证券之星消息，广信股份2025年中报显示，公司主营收入18.9亿元，同比下降17.36%；归母净利润3.51 亿元，同比下降14.95%；扣非净利润2.89亿元，同比下降22.32%；其中2025年第二季度，公司单季度主 营收入9.08亿元，同比下降15.25%；单季度归母净利润1.9亿元，同比上升1.38%；单季度扣非净利润 1.63亿元，同比上升4.07%；负债率34.74%，投资收益2542.67万元，财务费用-1.1亿元，毛利率 30.69%。 财报数据概要请见下图: 财务健康 经营效率 安全边际 估值倍数 相对成长性 未来回报率 股高率 l 股东情况 一 十大流通股东 一 2023 2024 2025 ■ 营业总收入-中报(亿) ■ 单季度营业总收入-第二季度(亿) 一 归母净利润 一 归母净利润-中报(亿) 3.51 同比 -14.94% 单季度归母净利润-第二季度(亿) 1.90 同比 +1.37% 10.22 5.01 4.12 3.5 1.89 1.87 2023 2024 2025 ■ 单季度归母净利润-第二季度(亿) ■ 归母净利润-中报(亿) 一 扣非净利润 一 扣非净利润-中报(亿) ...

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shenzhen) confirms that Shenzhen Noposion Crop Science Co., Ltd. has complied with relevant laws and regulations regarding the repurchase and cancellation of certain restricted stocks under its 2023 stock incentive plan [1][5][9] Group 1: Approval and Authorization for Repurchase - The company held its third extraordinary general meeting on December 4, 2023, where it approved the stock incentive plan and authorized the board of directors to handle related matters [5][6] - On August 18, 2025, the board of directors approved the repurchase of 187,500 shares of restricted stock that were granted but not unlocked, due to eight individuals leaving the company and one individual failing to meet performance standards [6][8] Group 2: Specifics of the Repurchase - The repurchase is based on the stock incentive plan, which states that restricted stocks will be repurchased if the recipient leaves the company or fails to meet performance criteria [7][8] - The repurchase price is set at 3.53 yuan per share plus interest from the bank's term deposits, resulting in a reduction of the total share capital from 1,004,821,310 shares to 1,004,633,810 shares after the repurchase [8][9] Group 3: Conclusion and Compliance - The legal opinion concludes that the repurchase has obtained necessary approvals and is in compliance with the Company Law, Securities Law, and relevant regulations [9]

深圳诺普信作物科学股份有限公司公告 证券代码：002215 证券简称：诺普信 公告编号：2025-041 深圳诺普信作物科学股份有限公司 关于2023年限制性股票激励计划回购注销已不符合激励条件 激励对象已获授但尚未解锁的限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳诺普信作物科学股份有限公司（以下简称"公司"）2025年8月18日召 开了第七届董事会第七次会议和第七届监事会第六次会议，会议审议通过了《关 于2023年限制性股票激励计划回购注销已不符合激励条件激励对象已获授但尚 未解锁的限制性股票的议案》。公司2023年限制性股票激励计划原激励对象孙伟 亮、唐爱军等8人因个人原因已离职；已不符合激励对象的条件，1名激励对象因 司回购注销。根据《公司2023年限制性股票激励计划（草案）及其摘要》的相关 规定，上述人员持有的187,500股限制性股票将由公司回购注销。本议案还需提 交公司股东大会审议，具体情况如下： 一、2023年限制性股票激励计划简述 议并通过了《关于公司2023年限制性股票激励计划（草案）及其摘要》、《公司 会办理公司2023 ...

深圳诺普信作物科学股份有限公司公告 证券代码：002215 证券简称：诺普信 公告编号：2025-038 深圳诺普信作物科学股份有限公司 第七届董事会第七次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 本议案需提交公司股东大会审议。 深圳诺普信作物科学股份有限公司公告 三、会议以同意5票，反对0票，弃权0票，审议通过《关于2025年坏账核销 的议案》。 本议案已经公司独董专门会议审议通过，具体内容详见2025年8月20日在《证 券时报》、《证券日报》、《中国证券报》、《上海证券报》和巨潮资讯网 http://www.cninfo.com.cn的《关于2025年坏账核销的公告》。 特此公告。 深圳诺普信作物科学股份有限公司董事会 二○二五年八月二十日 深圳诺普信作物科学股份有限公司（以下简称"公司"）第七届董事会第七 次会议通知于2025年8月8日以邮件方式送达。会议于2025年8月18日在公司会议 室以现场投票方式召开。应出席会议的董事5人，实际出席会议的董事5人，公司 监事、高级管理人员列席此次会议，会议符合《公司法》和《公司章程》的规定， 会议审 ...

经审核，监事会认为董事会编制和审核深圳诺普信作物科学股份有限公司 内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 二、会议以同意3票，反对0票，弃权0票，审议通过《关于2023年限制性 股票激励计划回购注销已不符合激励条件激励对象已获授但尚未解锁的限制 性股票的议案》。 根据《公司2023年限制性股票激励计划（草案）》的相关规定，公司2023 年限制性股票激励计划原激励对象孙伟亮、唐爱军等8人因个人原因已离职；已 不符合激励对象的条件，1名激励对象因2024年度绩效考核未达标，其所获授但 不符合解除限售条件的限制性股票将由公司回购注销。本次回购注销行为合法、 合规。我们同意将该议案提交公司股东大会审议。 深圳诺普信作物科学股份有限公司公告 证券代码：002215 证券简称：诺普信 公告编号：2025-039 深圳诺普信作物科学股份有限公司 第七届监事会第六次会议决议公告 本公司及监事会成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 深圳诺普信作物科学股份有限公司第七届监事会第六次会议通知于2025年8 月8日以邮件形式发出,会议于2025年 ...

Company Overview - Noposion (SZ 002215) announced its seventh board meeting on August 18, 2025, where it reviewed the 2025 semi-annual report [1] - As of the report, Noposion's market capitalization is 13.1 billion yuan [1] Revenue Composition - For the year 2024, Noposion's revenue composition is as follows: 43.73% from core business, 40.45% from supply chain business, and 15.81% from controlled distributors [1]

Core Viewpoint - Nopson (SZ 002215) reported a year-on-year increase in revenue and net profit for the first half of 2025, indicating positive growth trends in its financial performance [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 3.679 billion yuan, representing an 8.2% increase compared to the previous year [2] - The net profit attributable to shareholders was around 648 million yuan, reflecting a year-on-year increase of 17.35% [2] - Basic earnings per share were reported at 0.6614 yuan, which is also a 17.35% increase year-on-year [2]

Core Viewpoint - Nopson (002215.SZ) reported a revenue of 3.679 billion yuan for the first half of 2025, reflecting a year-on-year growth of 8.20% [1] - The net profit attributable to shareholders of the listed company reached 648 million yuan, marking a year-on-year increase of 17.35% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 679 million yuan, showing a year-on-year growth of 27.73% [1] - The basic earnings per share stood at 0.6614 yuan [1]

格隆汇8月19日丨诺普信(002215.SZ)公布2025年半年度报告，上半年公司实现营业收入36.79亿元，同比 增长8.20%；归属于上市公司股东的净利润6.48亿元，同比增长17.35%；归属于上市公司股东的扣除非 经常性损益的净利润6.79亿元，同比增长27.73%；基本每股收益0.6614元。 ...

Core Viewpoint - The company reported a positive financial performance for the first half of 2025, with significant growth in both revenue and net profit [1] Financial Performance - The company achieved operating revenue of 3.679 billion yuan, representing a year-on-year increase of 8.2% [1] - The net profit attributable to the parent company was 648 million yuan, reflecting a year-on-year growth of 17.35% [1] - Basic earnings per share were reported at 0.66 yuan [1] Business Strategy - The company is actively developing its blueberry channel and brand, focusing on building brands such as "Aimei Zhuang" and "Midie Lan" [1] - There is a strong emphasis on expanding key account (KA) customer relationships [1] - The company has successfully launched its products on major online platforms including JD.com, OLE, and Hema [1]